Table of Contents

• What are Tumor-Infiltrating Lymphocytes (TILs)?
• How TILs Work
• Conditions Treated with TILs
• The TIL Treatment Process
• Efficacy of TIL Therapy
• Safety and Side Effects
• Ongoing Research and Future Directions

What are Tumor-Infiltrating Lymphocytes (TILs)?

Autologous Tumor-Infiltrating Lymphocytes (TILs) are a type of immunotherapy that uses a patient’s own immune cells to fight cancer. TILs are T cells that have naturally migrated into a patient’s tumor tissue^[1]. These cells are extracted from the tumor, expanded in the laboratory, and then reinfused back into the patient to boost their cancer-fighting ability.

TIL therapy is considered an advanced therapy medicinal product and falls under the category of adoptive cell therapy^[2]. It is a personalized treatment approach that harnesses the power of the body’s own immune system to target and destroy cancer cells.

How TILs Work

The principle behind TIL therapy is to enhance the natural tumor-fighting ability of the patient’s immune system. Here’s how it works:

1. TILs are extracted from the patient’s tumor tissue during a biopsy or surgery.
2. In the laboratory, these TILs are isolated and multiplied to create a large population of cancer-fighting cells.
3. Before reinfusion, the patient typically undergoes a lymphodepleting chemotherapy regimen to create space for the new TILs and improve their effectiveness.
4. The expanded TILs are then infused back into the patient’s bloodstream.
5. Once in the body, these TILs seek out and attack cancer cells throughout the body.

TIL therapy is often combined with interleukin-2 (IL-2) administration, which helps to support the growth and activity of the infused T cells^[2].

Conditions Treated with TILs

TIL therapy is being investigated for several types of advanced or metastatic solid tumors, including:

• Melanoma: Both cutaneous and uveal melanoma^[2]
• Non-small cell lung cancer (NSCLC)^[3]
• Cervical cancer^[4]
• Head and neck squamous cell carcinoma (HNSCC)^[5]
• Other solid tumors associated with SWI/SNF complex mutations, such as:
  • Epithelioid sarcoma
  • Malignant rhabdoid tumor
  • Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)
  • Renal medullary carcinoma
  • Epithelioid malignant peripheral nerve sheath tumor (EMPNST)
  • Myoepithelial carcinoma
  • Extra-skeletal myxoid chondrosarcoma
  • Poorly differentiated chordoma
  • Sinonasal basaloid carcinoma^[1]

The TIL Treatment Process

The TIL treatment process typically involves the following steps:

1. Tumor harvesting: A tumor sample is surgically removed from the patient. This sample should be at least 1.5 cm in diameter to ensure enough TILs can be extracted^[4].
2. TIL isolation and expansion: In a specialized laboratory, TILs are isolated from the tumor sample and grown to large numbers (typically billions of cells) over several weeks.
3. Lymphodepletion: The patient undergoes a chemotherapy regimen (usually with cyclophosphamide and fludarabine) to deplete existing lymphocytes and create space for the new TILs^[2].
4. TIL infusion: The expanded TILs are infused back into the patient’s bloodstream.
5. IL-2 administration: High-dose interleukin-2 is often given after TIL infusion to support the survival and function of the infused cells.
6. Monitoring and follow-up: Patients are closely monitored for response to treatment and potential side effects.

Efficacy of TIL Therapy

Clinical trials are ongoing to evaluate the efficacy of TIL therapy in various cancer types. The primary measure of efficacy is often the objective response rate (ORR), which includes both complete and partial responses to treatment^[4].

Other important efficacy measures include:

• Duration of response (DOR): How long the response to treatment lasts
• Disease control rate (DCR): The percentage of patients whose disease does not progress
• Progression-free survival (PFS): The time from treatment until the disease progresses
• Overall survival (OS): The length of time patients live after starting treatment^[5]

Early results from clinical trials have shown promising efficacy in some cancer types, particularly in melanoma. However, more research is needed to fully understand the potential of TIL therapy across different cancer types and stages.

Safety and Side Effects

As with any cancer treatment, TIL therapy can cause side effects. Some potential side effects include:

• Side effects related to the lymphodepleting chemotherapy, such as decreased blood cell counts and increased risk of infection
• Cytokine release syndrome, which can cause fever, chills, and other flu-like symptoms
• Side effects related to IL-2 administration, which may include fever, chills, fatigue, and in some cases, more serious complications
• Potential autoimmune-like reactions^[2]

Patients are closely monitored during and after treatment to manage any side effects that may occur. The severity of side effects can vary from patient to patient.

Ongoing Research and Future Directions

Research on TIL therapy is ongoing, with several clinical trials investigating its use in various cancer types and combinations with other treatments. Some areas of current research include:

• Combining TIL therapy with checkpoint inhibitors to potentially enhance efficacy^[5]
• Exploring TIL therapy in new cancer types
• Investigating ways to improve TIL manufacturing and reduce production time
• Studying biomarkers that may predict response to TIL therapy
• Evaluating different IL-2 regimens or alternatives to support TIL function^[2]

As research progresses, our understanding of how to optimize TIL therapy and identify the patients most likely to benefit from it will continue to improve.